

ATTORNEY'S DOCKET NO. 24218

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		DATE: <u>04</u> May 2000 (<u>04</u> .05.2000)
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPL. NO. (if known): Not Yet Assigned 09/530693
INTERNATIONAL APPLICATION NO.: PCT/EP98/07033	INTERNATIONAL FILING DATE: 4 November 1998 (4.11.98)	PRIORITY DATE CLAIMED: 5 November 1997 (5.11.97)
TITLE OF INVENTION: USE OF VASOPRESSIN ANTAGONISTS		
APPLICANT(S) FOR DO/EO/US: ZENNER, Hans, Peter; RUPPERSBERG, J., Peter; LOWENHEIM, Hubert		
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <u>X</u> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <u> </u> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <u>X</u> This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <u>X</u> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <u>X</u> A copy of the International Application as filed (35 U.S.C. 371(c)(2)):</p> <p style="margin-left: 40px;">a. <u>X</u> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 40px;">b. <u> </u> has been transmitted by the International Bureau</p> <p style="margin-left: 40px;">c. <u> </u> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <u> </u> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <u>X</u> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 40px;">a. <u> </u> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 40px;">b. <u> </u> have been transmitted by the International Bureau.</p> <p style="margin-left: 40px;">c. <u> </u> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 40px;">d. <u>X</u> have not been made and will not be made.</p> <p>8. <u> </u> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <u> </u> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <u> </u> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5))</p>		
ITEMS 11. TO 16. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:		
11. <u> </u> An Information Disclosure Statement under 37 CFR 1.97 and 1.98		
12. <u> </u> An assignment document for recording A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included		
13. <u>X</u> A FIRST preliminary amendment		
<u> </u> A SECOND or SUBSEQUENT preliminary amendment		
14. <u> </u> A substitute specification.		
15. <u> </u> A change of power of attorney and/or address letter.		
16. <u>X</u> TRANSMITTAL FORM; FEE CALCULATION; INTERNATIONAL PUBLICATION WO 99/24051; INTERNATIONAL PUBLICATION DATE 20 MAY 1999; APPLICATION CONSISTING OF 21 PAGES INCLUDING; 14 PAGES TEXTUAL SPECIFICATION, 1 COVER SHEET CONTAINING THE ABSTRACT, 2 PAGES OF 20 CLAIMS; 4 SHEETS OF DRAWINGS; PRELIMINARY AMENDMENT, UNEXECUTED INVENTOR'S DECLARATION; PCT/IPEA/409 INTERNATIONAL PRELIMINARY EXAMINATION REPORT, PCT/ISA/210 INTERNATIONAL SEARCH REPORT; PCT/RO/101 PCT REQUEST; PCT/IB/304 NOTIFICATION CONCERNING SUBMISSION OF PRIORITY DOCUMENT, PCT/IB/332 NOTIFICATION TO ELECTED OFFICES INFORMING TO THEIR ELECTION; PCT/IPEA/402 NOTIFICATION OF RECEIPT OF DEMAND, PCT/IB/306/ NOTIFICATION OF THE RECORDING OF A CHANGE		

BOX PCT

ATTORNEY'S DOCKET NO. 24218

U.S. APPLICATION NO. (If known) Not Yet Assigned 097530693		INTERNATIONAL APPLICATION NO. PCT/EP98/07033		DATE 04 MAY 2000 (04 05 2000)	
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO:.....\$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00 International preliminary examination fee (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				<u>CALCULATIONS</u> \$840.00 \$840.00	<u>PTO USE ONLY</u>
Surcharge of \$130.00 for furnishing the oath or declaration later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 00.00	
CLAIMS	NO. FILED	NO. EXTRA	RATE		
TOTAL	20 -20=	0	0 X \$ 18.00	\$	840.00
INDEPENDENT	3 - 3=	0	0 X \$ 78.00	\$	0.00
Multiple dependent claims(s) (if applicable)			+ \$260.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	840.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	0.00
SUBTOTAL =				\$	840.00
Processing fee of \$130.00 for furnishing the English translation later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0.00
TOTAL NATIONAL FEE =				\$	840.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	0.00
TOTAL FEES ENCLOSED =				\$	840.00
				Amount to be:	
				refunded	\$
				charged	\$

ATTORNEY'S DOCKET NO. 24218

U.S. APPLICATION NO. <small>(if known)</small> 09/530693	INTERNATIONAL APPLICATION NO PCT/EP98/07033	DATE: 04 May 2000 (04.05.2000)
--	--	---------------------------------

a. ☒ One check in the amount of \$840.00 to cover the above fees ,is enclosed.

b. ☐ Please charge my Deposit Account No. 14-0112 in the amount of \$_____ to cover the above fees. (A duplicate copy of this sheet is enclosed.)


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0112.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed to request that the application be restored to pending status.

Send All Correspondence To:

Gary M. Nath
 NATH & ASSOCIATES, PLLC
 1030 15th Street, N.W.
 Sixth Floor
 Washington, D.C. 20005

(202) 775-8383 (phone)
 (202) 775-8396 (fax)



 GARY M. NATH
 Registration Number 26,965

Rev. 02/98

BOX PCT

Attorney Docket No. 24218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ZENNER, Hans Peter; RUPPERSBERG, J. Peter; LÖWENHEIM, Hubert

International Application No. PCT/EP98/07033

Serial No. NOT YET ASSIGNED

International Filing Date: 4 November 1998 (04.11.98)

Filed: May 4, 2000

For: **USE OF VASOPRESSIN ANTAGONISTS**

PRELIMINARY AMENDMENT

The Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Before calculating the filing fee for the above identified application, please enter the following amendments:

IN THE CLAIMS:

Claim 1. (Amended) A method of treating disturbances or illnesses of an inner ear, comprising administering [Use of] at least one vasopressin receptor antagonist or mixtures of such antagonists [for the treatment of disturbances or illnesses of the inner ear] to a patient in need thereof.

Claim 2. (Amended) The method of [Use according to] claim 1, characterized in that the receptor antagonist is a vasopressin-V₂-receptor antagonist.

Claim 3. (Amended) The method of [Use according to] claim 1 [or 2], characterized in that the disturbance or illness of the inner ear is associated with at least one of the symptoms vertigo, impairment of hearing or tinnitus.

09/530693-07033

Claim 4. (Amended) The method of [Use according to] claim 3, characterized in that the impairment of hearing is a deep sound hearing impairment.

Claim 5. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the disturbance or illness of the inner ear is linked with a hydrops, particularly an endolymphatic hydrops.

Claim 6. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the disturbance or illness of the inner ear is Menière's disease.

Claim 7. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is a peptide compound.

Claim 8. (Amended) The method of [Use according to] claim 7, characterized in that the peptide compound is a linear peptide, particularly propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH₂.

Claim 9. (Amended) The method of claim 1 [Use according to one of the claims 1 to 6], characterized in that the receptor antagonist is a non-peptidic, preferably non-peptidic, organic substance.

Claim 10. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is a benzazepin

derivative.

Claim 11. (Amended) The method of [Use according to] claim 10, characterized in that the benzazepin derivative is 5-dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

Claim 12. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is an indole derivative.

Claim 13. (Amended) The method of [Use according to] claim 12, characterized in that the indole derivative is 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate.

Claim 14. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist can be administered orally and/or intravenously, particularly orally.

Claim 15. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is used in a quantity of 0.1 to 50 mg/kg of body weight and per day.

Claim 16. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor

antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

Claim 18. (Amended) The process [Process] according to claim 17, characterized by [at least one of the features of claims 2 to 16] the features of claim 2.

Claim 20. (Amended) The composition [Composition] or medicament according to claim 19, characterized by [at least one of the features of claims 7 to 16] the features of claim 7.

REMARKS

Claims 1-20 are pending in the present application. The amendments do not add any new matter under 35 U.S.C. §132. The amendments have been made to remove multiple dependencies from the claims and to convert the use claims into method claim format. Accordingly, entry of the amendments prior to examination of the application is respectfully requested.

CONCLUSION

In view of the foregoing, Applicants respectfully request the Examiner to allow all claims pending in this application. If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

- 1) Hans Peter ZENNER
- 2) J. Peter RUPPERSBERG
- 3) Hubert LOEWENHEIM

Applicant or Patentee: _____
 Serial or Patent No.: _____
 Attorney Docket No.: _____
 Filed or Issued: _____
 For: Use of vasopressin antagonists

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 C.F.R. 1.9(f) and 1.27(c)-SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern
 identified below
☒ an official of the small business
 concern empowered to act on behalf of the concern
 identified below:

NAME OF CONCERN Otogene Aktiengesellschaft
 ADDRESS OF CONCERN Vor dem Kreuzberg 17, D-72070 Tuebingen

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. 121.3-18, and reproduced in 37 C.F.R. 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees in the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled _____
Use of vasopressin antagonists

by inventor 1) Hans Peter ZENNER, 2) J. Peter RUPPERSBERG, 3) Hubert LOEWENHEIM
 described in

- ☒ the specification filed herewith
☐ application serial no. _____,
 filed _____.
☐ patent no. _____,
 issued _____.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R.

1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or a nonprofit organization under 37 C.F.R. 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 C.F.R. 1.27)

NAME Otogene Aktiengesellschaft

ADDRESS Vor dem Kreuzberg 17, D-72070 Tübingen

[] INDIVIDUAL [X] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dr. Christof Antz Hans-Jörg Bergler
 TITLE OF PERSON OTHER THAN OWNER X CSO CFO
 ADDRESS OF PERSON SIGNING Schwärzlocher Str.60 Gottlob Breuning Str. 8
72070 Tübingen 72070 Tübingen
 SIGNATURE *Antz* DATE 29.05.2000

Hans-Jörg Bergler

DESCRIPTION

USE OF VASOPRESSIN ANTAGONISTS

The invention relates to the use of at least one vasopressin receptor antagonist or mixtures thereof.

As is known, vasopressin (VP) is a peptide hormone from the posterior lobe of the hypophysis. As a result of its antidiuretic action it is also known as antidiuretin or antidiuretic hormone (ADH). The hormone form occurring in humans and many mammals is a cyclic peptide of nine amino acids with a disulphide bridge, in which arginine is in the eight-position. This form is correspondingly also known as arginine vasopressin (AVP).

As stated, the influence of vasopressin in water diuresis in the kidneys, namely the antidiuretic action which it produces, is physiologically particularly important. Vasopressin makes the collecting tubules in the kidney permeable to water and in this way permits the re-resorption of water in the kidneys and consequently the concentration of the urine. The epithelial tissues of the collecting tubules react to the presence of vasopressin. The hormone supplied from the blood side of the epithelial cells is bound to specific receptors and by means of intracellular cAMP (second messenger cyclic adenosine-3',5-monophosphate) stimulates the increase in water permeability. The fundamental mechanism can be conceived in such a way that water channel-forming glycoproteins are formed in the so-called chief cells. In the case of the chief cells of the collecting tubules of the kidney, this glycoprotein is the hitherto solely detected aquaporine-2 there. It is initially stored in small vesicles in the cell interior and in the presence of vasopressin at the receptor is incorporated into the apical cell membrane. As a result the hormonally regulated water entry into the cell is permitted.

Vasopressin receptors which bring about a cAMP-dependent water channel regulation in the epithelial cells of the collecting tubules in the kidney are known as V_2 receptors.

Thus, in the epithelial cells of the collecting tubules of the kidney, vasopressin has a water-re-resorbing action. This can be inhibited by vasopressin receptor antagonists. Correspondingly said antagonists in the kidney

In conjunction with the antidiuretic action of vasopressin already vasopressin receptor antagonists are known. These can be peptidic or non-peptidic substances. In connection with the peptidic substances reference is made to the publications of M. Manning and W.H. Sawyer in J. Lab. Clin. Med. 114, 617-632 (1989) and F.A. Laszlo et al. in Pharmacol. Rev., 43, 73-108 (1991). Descriptions of non-peptidic substances appear in Y. Yamamura et al. in Br. J. Pharmacol. 105, 787-791 (1992) and C. Serradeil-Le Gal et al. in J. Clin. Invest., 98 (12), 2729-2738 (1996). All these substances are investigated and used in connection with the antidiuretic action of the vasopressin.

Findings and investigations up to now concerning disturbances and illnesses of the inner ear cannot be brought into accord with the above-described findings concerning the antidiuretic action of vasopressin and the inhibition of this action by antagonists. This particularly also applies to the so-called endolymphatic hydrops in the inner ear, in which there is an endolymph fluid excess in the endolymphatic area of the inner ear. This endolymphatic hydrops can be linked with an overproduction or outflow or discharge disturbance of the endolymph, particularly in the so-called endolymphatic sac (*Saccus endolymphaticus*). Although the existence of vasopressin has been detected in the inner ear, a use of vasopressin antagonists cannot be considered as a result of the existing findings concerning the water-re-resorbing action of vasopressin. In the case of an increased liquid volume in the inner ear, which can trigger illness symptoms, the known action of vasopressin would be desired. This action would be inhibited by the use of the antagonist.

It has now surprisingly been found that in the inner ear, particularly in the epithelium of cells, which include the endolymph, the water permeability can be restored and improved by the use of vasopressin receptor antagonists. As a result of this unexpected, opposing action of the antagonist compared with its action in the kidney, the use of such substances or their mixtures for the treatment of disturbances or illnesses to the inner ear is made

possible.

Thus, the problem of the invention of making available active ingredients for the treatment of disturbances or illnesses in the inner ear, is solved by the use according to claim 1. Preferred developments are given in the dependent claims 2 to 16. The content of all these claims is hereby made by reference into part of the content of the description.

According to the invention, at least one vasopressin receptor antagonist or mixtures thereof can be used for treatment of disturbances or illnesses of the inner ear. This in particular also covers the use for producing a corresponding medicament or a corresponding pharmaceutical composition and the antagonist can optionally be used in the form of its pharmaceutically acceptable salts and optionally mixed with a pharmaceutically acceptable carrier or diluent.

The receptor antagonists used according to the invention are preferably those which interact with one of the aforementioned V_2 receptors. According to the present state of knowledge these V_2 receptors are the ones which are mainly linked with the antidiuretic action of vasopressin.

The disturbance or illness of the inner ear which is to be treated with the use according to the invention is preferably associated with one of the symptoms vertigo (vestibular disorders), impairment of hearing, tinnitus aurium or a pressure feeling in the ear. The symptoms vertigo, impairment of hearing or tinnitus are particularly stressed. In the use according to the invention one of these symptoms can occur alone, but there can also be a random combination of two or three symptoms or also the occurrence of all three or four symptoms are typical in the case of inner ear disturbances.

The hearing impairment symptom can in particular occur as so-called deep sound hearing impairment, preferably as fluctuating deep sound hearing impairment.

The inner ear disturbances or illnesses treatable through the use according to the invention can, according to the present state of knowledge, frequently

and preferably be linked with a so-called hydrops, particularly an endolymphatic hydrops. As is known a hydrops is a fluid accumulation or fluid collection in the body, particularly in the cavities present therein. In the case of the aforementioned endolymphatic hydrops it is a fluid excess of the so-called endolymph. This fluid excess can be attributed to an overproduction or an outflow disturbance of the endolymph, particularly in the so-called endolymphatic sac. Endolymphatic hydrops leads to an increased pressure and a volume increase in the space in which the endolymph is located. As with this is associated a modified deflectibility of the sensory hairs, which are responsible for hearing and vestibular sense, said symptoms, particularly vertigo, impairment of hearing and tinnitus, can be explained with an endolymphatic hydrops.

Among the treatable disturbances or illnesses particular reference is made to Menière's disease, which is normally associated with the symptoms vertigo, impairment of hearing and tinnitus aurium. There can be numerous influences acting as triggers for Menière's disease such as e.g. stress, infections, tumours, immunological or neurogenic disturbances, etc. In the present case Menière's disease is to be understood as a collective term for disturbances in which the corresponding symptoms can occur with different intensities, such as e.g. as vestibular Menière's disease. Another possible application is Lermoyez disease. Preferably disturbances/illnesses of the inner ear can be treatable, which manifest themselves in deep sound hearing impairment. Corresponding deep sound hearing impairments frequently also arise following inflammatory illnesses, such as insidious middle ear inflammation or syphilis, in the case of toxic influences or as delayed hydrops syndrome, or also as a consequence of venous stasis or vascular disturbances of the inner ear. All disturbances/illnesses of the inner ear, which in addition to those indicated hereinbefore can also be linked with outflow disturbances of the endolymph in the endolymphatic sac are possibly suitable for the use of the present invention.

According to the invention it is possible to use known or also further novel vasopressin receptor antagonists, particularly vasopressin- V_2 -receptor antagonists. These substances, like vasopressin, can be peptide compounds, which in the same way as vasopressin interact with the receptor. Such peptide

compounds are e.g. disclosed in the aforementioned publication of M. Manning and W.H. Sawyer. These can in particular be comparatively easily accessible linear peptides and in particular it is possible to use the peptide propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH₂. The components of the reproduced peptide sequence have the standard meaning in biochemistry and Abu is α -L-aminobutyric acid. A selection of linear peptide compounds in principle usable as vasopressin receptor antagonists, including the particularly stressed compound, appear in the publication of M. Manning et al in Int. J. Peptide Protein Res., 32, 455-467 (1988). The compound reproduced above with its peptide sequence is marketed by BACHEM Feinchemikalien AG, Bubendorf, Switzerland, under product No. H-9400.

It is fundamentally also possible to use non-peptidic receptor antagonists for vasopressin and these are preferably non-peptidic organic substances, which once again are preferably synthetically produced. In the case of the hitherto known organic substances these can be benzazepin derivatives, such as are e.g. described in EP-A1-514667. Particular reference is made to the substance 5-dimethylamino-1-{4-(2-methylbenzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin, described under the name OPC-31260 in the publication of Y. Yamamura et al. in Br. J. Pharmacol. 105, 787-791 (1992). The content of this publication is by reference made into part of the content of the present description. Other possible non-peptidic organic substances are indole derivatives, as are known fundamentally from WO 93/15051, WO 95/18105 and EP-A1-645375. As a N-sulphonyl-2-oxoindole derivative, particular reference is made to 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate described under the name SR 121463A in J. Clin. Invest. 98 (12), 2729-2738 (1996).

According to the invention it is preferable for the receptor antagonist to be orally and/or intravenously administrable. An oral administration possibility, as in the case of non-peptidic receptor antagonists compared with peptidic receptor antagonists for vasopressin, is particularly favourable, because this greatly facilitates administration possibilities to a patient.

The use according to the invention of vasopressin receptor antagonists can

fundamentally take place in random ways and the selected administration form can be adapted to the age, sex or other characteristics of the patient, the severity of the disturbances/illnesses and other parameters. When using oral administration it is e.g. possible to produce tablets, pills, solutions, suspensions, emulsions, granules or capsules. Conventional pharmaceutical carriers, diluents or conventional additives can be present. For intravenous administration the antagonists can be provided alone or together with conventional auxiliary fluids, such as e.g. glucose, amino acid solutions, etc. A preparation for intramuscular, subcutaneous or interperitoneal administration is optionally also possible. An administration in suppository form is also conceivable.

The dosage can fundamentally be freely selected as a function of the clinical picture and the conditioning of the patient. Conventionally use is made of quantities of 0.1 to 50 mg/kg of body weight and per day. Per dosage unit the receptor antagonist for vasopressin is conventionally contained in a quantity of approximately 10 to 1,000 mg per unit. In a formulation or a corresponding medicament provided for administration the receptor antagonist for vasopressin is preferably contained in a quantity of 1 to 75 wt.%. Within this range values between 5 and 50 wt.%, particularly 5 and 25 wt.% are preferred.

The use of a formulation prepared according to the invention or a corresponding medicament fundamentally takes place systemically, preference being given to the aforementioned oral route. In certain circumstances a local application in the direction of the inner ear is possible, if e.g. as a result of an operation an access to the inner ear can be made. Thus, the application of drainage following exposure of the endolymphatic sac is possible and then e.g. with the aid of a pump via a corresponding catheter the vasopressin receptor antagonist can be passed directly to the action location of a corresponding inner ear disturbance/illness.

The invention also covers a process for the treatment of disturbances or illnesses of the inner ear and which is characterized in that at least one vasopressin receptor antagonist or mixtures thereof is administered in a suitable quantity for the body of the animal or person being treated. In

The invention finally covers a pharmaceutical composition or a medicament for the treatment of disturbances or illnesses of the inner ear, which contains at least one vasopressin receptor antagonist or mixtures thereof. In connection with the individual features of such a composition or medicament, reference is once again made to the corresponding description text up to now.

In the drawings show:

a without vasopressin addition
b with chronic vasopressin addition
c with acute vasopressin addition
d with acute vasopressin addition (detail enlargement)

a V_2 receptor and
b aquaporin-2

c in the epithelium with ^{125}I -vasopressin

d control test in the presence of unlabelled vasopressin

Fig. 4 Organotypical culture of the endolymphatic sac of the rat

- a overall radiogram
- b infrared light microscopy
- c SEM radiogram
- d SEM radiogram (greater magnification)

Fig. 5 Membrane turnover in the culture according to fig. 4

- a FITC-dextran-labelled endosomes in the absence of vasopressin
- b FITC-dextran-labelled endosomes in the presence of vasopressin
- c SEM radiogram in case a
- d SEM radiogram in case b
- e FITC-dextran-labelled endosomes in the presence of forskolin
- f FITC-dextran-labelled endosomes in the presence of choleratoxin
- g FITC-dextran-labelled endosomes in the presence of vasopressin and V_2 receptor antagonist H-9400.

Experiment 1

Guinea pigs with a normal Preyer reflex and weighing between 300 and 500 g were used for the investigation. For investigating the acute action of vasopressin Pitressin^(R) (arginine-vasopressin AVP) from Sankyo, Japan was intraperitoneally injected (0.2 units/g). For histology the guinea pigs were killed two hours after the injection. For the chronic experiments 0.5 units/g of vasopressin were subcutaneously administered for 60 days once a day. For investigating the acute action use was made of 20 animals and for the investigation of the chronic action 10 animals. For comparison purposes in the case of the 10 control animals 0.2 ml of physiological common salt solution was intraperitoneally injected. The cochleae of all the test animals were embedded in celloidin and the mid-modiolar sections were dyed with hematoxylin/eosin (HE). As a result of the deflection of Reissner's membrane the presence of an endolymphatic hydrops was determined.

The results of experiment 1 are represented in fig. 1.

Fig. 1a shows that the Reissner's membrane indicated in exemplified manner by an arrow is not deflected in the control animals (n = 10) and

correspondingly there is no endolymphatic hydrops.

According to fig. 1b in the case of a test animal with chronic administration of vasopressin (n = 10) it is possible to detect a strong endolymphatic hydrops as a result of the pronounced displacement of Reissner's membrane. In the cochlear spiral, which corresponds to that marked with the arrow in fig. 1a, the Reissner's membrane is even in contact with the bony septum between spiral turns 3 and 4. Four of the ten test animals chronically treated with vasopressin had severe hydrops according to fig. 1b and three others had slight to moderate hydrops.

Fig. 1c shows a slight to moderate endolymphatic hydrops in a test animal following a single injection of vasopressin, i.e. acute treatment. At n = 20 eight of these twenty test animals had such slight to moderate hydrops. Fig. 1d shows the same case as fig. 1c, but with a higher magnification. As opposed to fig. 1b no contact with the bony septum is detectable, but there are clear protrusions of Reissner's membrane.

Thus, experiment 1 and the associated fig. 1 show that increased plasma values of vasopressin can give rise to an endolymphatic hydrops.

Experiment 2

Using the primers AQP2s, AQP2as, V2s and V2as PCR (polymerase-chain reaction) experiments were performed. The primers had the following nucleotide sequences:

AQP2s	GAT CGC CGT GGC CTT TGG TCT
AQP2as	AGG GAG CGG GCT GGA TTC AT
V2s	AGT GCT GGG GGC CCT AAT ACG
V2as	CAA ATC GGG CCC AGC AAT CAA ACA

The cDNAs of aquaporin-2 and the V₂ receptor were amplified by the use of the primer pairs AQP2s/AQP2as and V2s/V2as. The PCRs were performed in a total volume of 50 µl containing 5 µl of reverse transcriptase, in each case 0.8 µM of primer, in each case 200 µM of dNTPs, an incubation buffer

(containing 1.5 mM $MgCl_2$ from Pharmacia) and 1.25 U of Taq polymerase (also from Pharmacia). Following a denaturation step of 7.5 min at 94°C at the start there were 40 cycles lasting 50 sec at 94°C, 50 sec at 55°C and 50 sec at 72°C and a ten minute stage at 72°C to the end. The expected product lengths were 428 bp and 419 bp. The PCR products were worked up in the usual way and detected by subcloning and sequencing.

As can be gathered from fig. 2, both V_2 receptor and aquaporin-2 were strongly expressed in the epithelium of the endolymphatic sac, whereas in other epithelia of the inner ear, also in contact with the endolymph, such a detection was unsuccessful.

According to fig. 2a in the inner ear of the rat the V_2 receptor could be detected both on the postnatal day 4 (p4) and in the grown rat (ad). Very weak bands were obtained in the endolymphatic sac on postnatal day 1 (p1), in the stria vascularis (StV), in the vestibular organ (V) or in Reissner's membrane (RM). According to fig. 2b the expression of aquaporin-2 was most clearly detectable in the grown endolymphatic sac on postnatal day 4, but it was not possible to detect any expression in the stria vascularis, the vestibular organ or Reissner's membrane.

Experiment 3

Human endolymphatic sac was obtained from six autopsies and two patients who had undergone operations with the authorization of relatives or the patients. Frozen sections (20 μm) were sectioned on a cryostat at -16°C, applied to gelatin-coated platelets and stored overnight in vacuo at 4°C. The tissue sections were incubated overnight at 4°C with ^{125}I -arginine-vasopressin in the absence (total binding) or presence of 10 μM of unlabelled arginine-vasopressin (unspecific binding), namely in ice cold 10 mM tris-HCl buffer (pH 7.4) containing 10 mg of $MgCl_2$, 0.5 mg/ml of bacitracin and 0.1% bovine serum albumin. The radio-labelled sections were coated with NTB-2 nuclear emulsion (Eastman Kodak) and prepared for light microscopic autoradiography. The coated plates were stored 3 to 8 days in the dark at 4°C. After development and fixing the plates were dyed with hemotoxylin/eosin.

Fig. 3 shows the results of experiment 3. It is possible to see the specific binding of radioactive vasopressin in the human endolymphatic sac. The dots in fig. 3c show the binding of the vasopressin in the epithelium of the endolymphatic sac, whilst according to fig. 3d the same treatment in the presence of unlabelled vasopressin excludes an unspecific vasopressin binding in the sac.

Experiment 4

On postnatal day 4 rats were put to sleep using sodium pentobarbital (0.4 mg/gr body weight) and then decapitated. The temporal bones were immediately removed and transferred into cold (4°C) HEPES-buffered common salt solution with salt solution (HHBSS) adjusted with Hank's. The complete endolymphatic sac was separated from the temporal bone, opened at the corner of the distal sac part and inserted flat in a culture plate, which was coated with 20 µl of Cell Tek of Becton Dickinson Labware, USA, with a dilution of 1:5 and covered with 300 µl of culture medium. The culture medium consisted of minimum essential medium with D-valine, in order to suppress the growth of fibroblasts and which was supplemented with 10% foetal calf serum (FCS), 10 mM HEPES, 100 IU/ml penicillin and 2 mM glutamine. The cultures were kept in a 5% carbon dioxide atmosphere at 37°C for up to 5 days. The morphology of the culture was observed by infrared light microscopy. A detailed surface morphology of the epithelia was obtained by SEM (scanning electron microscopy). The cover slips of the explants were fixed for 120 min in 2.5% glutaraldehyde, 0.1 M sodium cacodylate buffer, re-fixed for 60 min in 1% osmium tetroxide, washed, dried, gold-coated according to a standard process and investigated in a Hitachi 500-SEM.

Fig. 4 shows the results of experiment 4.

Fig. 4a provides a survey of an endolymphatic sac after 4 days in the culture, proximal (PSP), intermediate (ISP) and distal (DSP) sac parts being shown. The structural analysis of the culture epithelium of the endolymphatic sac shown in fig. 4b and 4c shows a clear similarity with the native organ with mitochondria-rich and ribosome-rich cells of a typical configuration. Thus, the radiogram of the infrared light microscope shows individual cells in the

intermediate part and two cell types can differ on the basis of configuration and surface morphology. The polygonally shaped cells corresponding to the ribosome-rich cells (RRC) have a flat surface, whereas the round cells corresponding to the mitochondria-rich cells (MRC) have numerous microvilli projecting into the opening. This is also clearly visible from the SEM radiogram according to fig. 4c. The greater magnification according to fig. 4d additionally clearly shows the clathrin-coated pits of the luminal cell membrane in the RRC cells of the endolymphatic sac (cf. arrow).

Experiment 5

In a culture according to experiment 4 following 12 hours culturing of the endolymphatic sac in HHBSS (pH 7.3), which contained 1.0 mg/ml of fluorescein isothiocyanate (FITC)-dextran (from Sigma, Germany), incubation took place for approximately 10 min at 37°C. The endolymphatic sac was then washed with HHBSS and fixed for 20 min in PBS with 4% paraformaldehyde. Fluorescence and interference contrast images were recorded by an epifluorescence microscope (Olympus AX-70, Germany) with a standard FITC filter set (excitation: 485 ± 20 nm; emission: > 510 nm) and superimposed in order to render visible also the non-fluorescing cells and to discriminate the mitochondria-rich and ribosome-rich cells.

Subsequently vasopressin, forskolin, cholera toxin (all from Sigma, Germany) or V_2 receptor antagonist H-9400 (BACHEM, Switzerland) were added to the solutions together with the FITC dextran, namely in the quantities described herinafter.

Fig. 5 shows the results of experiment 5.

Thus, fig. 5a shows the endocytosis represented by the FITC dextran-labelled endosomes and observed in the culture of the endolymphatic sac in RRC and MRC in the absence of further substances, i.e. in a control experiment ($n = 120$). On adding 1 nM of vasopressin ($n = 84$) the membrane turnover in RRC is inhibited, i.e. no labelled endosomes are visible in RRC. Labelled endosomes are still observed in MRC. This means that in the endolymphatic sac the vasopressin (as opposed to the situation in the epithelium of the

collecting tubules of the kidney) inhibits the absorption of FITC dextran in ribosome-rich cells (RRC). Thus, in the example according to fig. 5b 10.5 ± 2.1 of 118.5 ± 2.8 cells reveal FITC dextran absorption ($n = 20$) compared with an untreated specimen according to the example of fig. 5a in which 90.5 ± 2.5 of 116.5 ± 2.4 cells revealed FITC dextran absorption (at $n = 20$).

The inhibitory effect of vasopressin on the membrane turnover is also demonstrated by the disappearance of the clathrin-coated pits from the apical cell surface of the ribosome-rich cells in accordance with the SEM radiograms of figs. 5c and 5d. Thus, under control conditions RRC revealed numerous coated pits (cf. arrow in fig. 5c), which were shown with a greater magnification in fig. 4d. The crossbar in fig. 5d represents a length of 1 μ m. Following a treatment with 1 mM of vasopressin according to fig. 5d almost no holes are visible, which reveals the internalization of the probably aquaporin-2-clustered clathrin.

As in the case of vasopressin, according to fig. 5e and 5f almost no endosomes were detected when using 50 μ M of forskolin ($n = 48$) or 0.1 nM of cholera toxin ($n = 36$).

Just as surprising as the result of the experiment shown in fig. 5b is the test result according to fig. 5g, in which a simultaneous application of 10 nM of vasopressin and 10 nM of \bar{V}_2 receptor antagonist H-9400 cancelled out the vasopressin effect according to fig. 5b. The FITC dextran-filled endosomes are still present (test number $n = 30$).

The described FITC dextran tests make use of the known fact that the membrane turnover can be represented by FITC dextran and can be correlated with the water transport through the membrane. A high membrane turnover revealed by FITC dextran makes it possible to conclude that there is a high water transport. As the epithelium of the endolymphatic sac comprises almost exclusively RRC and MRC cells, the proof provided according to experiment 5 is valid for the complete endolymphatic sac and the supplying duct. The results are also in accordance with the fact that vasopressin is active on the RRC cells and consequently the effect of vasopressin or vasopressin antagonist can be detected there. The MRC cells are not active with vasopressin and

correspondingly reveal no effect according to experiment 5.

Due to the fact that the peptidic antagonist H-9400 used is a comparatively selective V_2 receptor antagonist, the test results constitute a strong indication that the vasopressin receptor at the endolymphatic sac of the inner ear is of the V_2 type. However, surprisingly the vasopressin in the inner ear clearly has a reverse action to that in the epithelial cells of the collecting tubule of the kidney. This explains the surprising result that the vasopressin receptor antagonist increases membrane turnover and consequently water transport as opposed to the known actions in the kidney and consequently a water-resorbing action is obtained through the use of the antagonist. This systematic finding makes the use according to the invention of the vasopressin receptor antagonist for the treatment of illnesses or disturbances of the inner ear, particularly those associated with a hydrops, such as an endolymphatic hydrops, possible. An antagonist action associated with a volume decrease on the luminal side, unlike the known action in the kidney, in the inner ear in the case of an overpressure or an excessive volume leads to a pressure and volume decrease. These are suitable for ameliorating or eliminating the symptoms, i.e. in particular vertigo, impairment of hearing and tinnitus. The use according to the invention can also have a prophylactic effect with such inner ear disturbances.

CLAIMS

1. Use of at least one vasopressin receptor antagonist or mixtures of such antagonists for the treatment of disturbances or illnesses of the inner ear.
2. Use according to claim 1, characterized in that the receptor antagonist is a vasopressin- V_2 -receptor antagonist.
3. Use according to claim 1 or 2, characterized in that the disturbance or illness of the inner ear is associated with at least one of the symptoms vertigo, impairment of hearing or tinnitus.
4. Use according to claim 3, characterized in that the impairment of hearing is a deep sound hearing impairment.
5. Use according to one of the preceding claims, characterized in that the disturbance or illness of the inner ear is linked with a hydrops, particularly an endolymphatic hydrops.
6. Use according to one of the preceding claims, characterized in that the disturbance or illness of the inner ear is Menière's disease.
7. Use according to one of the preceding claims, characterized in that the receptor antagonist is a peptide compound.
8. Use according to claim 7, characterized in that the peptide compound is a linear peptide, particularly propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH₂.
9. Use according to one of the claims 1 to 6, characterized in that the receptor antagonist is a non-peptidic, preferably non-peptidic, organic substance.
10. Use according to claim 9, characterized in that the organic substance is a benzazepin derivative.

11. Use according to claim 10, characterized in that the benzazepin derivative is 5-dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

12. Use according to claim 9, characterized in that the organic substance is an indole derivative.

13. Use according to claim 12, characterized in that the indole derivative is 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate.

14. Use according to one of the preceding claims, characterized in that the receptor antagonist can be administered orally and/or intravenously, particularly orally.

15. Use according to one of the preceding claims, characterized in that the receptor antagonist is used in a quantity of 0.1 to 50 mg/kg of body weight and per day.

16. Use according to one of the preceding claims, characterized in that the receptor antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

17. Process for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is administered in a suitable, compatible quantity.

18. Process according to claim 17, characterized by at least one of the features of claims 2 to 16.

19. Pharmaceutical composition or medicament for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is contained.


20. Composition or medicament according to claim 19, characterized by at least one of the features of claims 7 to 16.

USE OF VASOPRESSIN ANTAGONISTS

The invention relates to the application of at least one vasopressin receptor antagonist or mixture of such antagonists in order to treat disturbances or illnesses of the inner ear. These disturbances/illnesses can be connected to at least one of the following symptoms: vertigo, impairment of hearing or tinnitus. The symptoms can especially relate to those of so-called Menière's disease. According to the invention, especially vasopressin V₂ receptor antagonists can be applied, whereby the antagonists can be peptidic or non-peptidic substances.



A 33 153 PCT

1/4

Abb. 1


A 33 153 PCT

2/4

Abb. 2Abb. 3

A 33 153 PCT

3/4

Abb. 4

DECLARATION FOR PATENT APPLICATION

Attorney Docket: 24218

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original inventor, first and sole (if only one name is listed below) or the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed, and for which a patent is sought on the invention entitled:

Use of vasopressin antagonists
the specification of which: (check one)

☐ is attached hereto.

☒ was filed on 4 Nov. 1998, as Serial No. PCT/EP 98/07033,
4 May 2000 09/530,693
and was amended on _____ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications:

197 48 763.7

(Application No.)

Germany

(Country)

05 / 11 / 1997

(Day/Month/Year Filed)

Priority Claimed

☒ ☐

Yes No

(Application No.)

(Country)

(Day/Month/Year Filed)

☐ ☐

Yes No

(Application No.)

(Country)

(Day/Month/Year Filed)

☐ ☐

Yes No

We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Suet M. Chong, Reg. No. 38,104; Todd L. Juneau, Reg. No. 40,669; Patricia M. Drost, Reg. No. 29,790; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Joshua B. Goldberg, Reg. No. 44,126; David Milligan, Reg. No. 42,893 and Robert G. Lev, Reg. No. 30,280; David R. Murphy, Reg. No. 22,751; Paul A. Sacher, Reg. No. 43,418; Gregory B. Kang, Reg. No. P-45,273; Scott F. Yarnell, P-45,245; as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Gary M. Nath
(202) 775-8383

Send Correspondence to:

NATH & ASSOCIATES
Sixth Floor
1030 15th Street, N.W.
Washington, D.C. 20005 U.S.A.

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. § 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.) (U.S. Filing Date) (Status--patented, pending, abandoned)

(U.S. Application Serial No.) (U.S. Filing Date) (Status--patented, pending, abandoned)

DECLARATION FOR PATENT APPLICATION

Attorney Docket 24218

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Hans Peter ZENNERInventor's Signature [Signature]Date 28.05.2000Residence: D-72070 Tuebingen - GermanyCountry of Citizenship: GermanyPost Office Address: Burgholzweg 149, D-72070 Tuebingen, GermanyFull name of second inventor: J. Peter RUPPERSBERGInventor's Signature [Signature]Date 29.5.2000Residence: D-72072 Tuebingen, GermanyCountry of Citizenship: GermanyPost Office Address: Allensteiner Weg 5, D-72072 Tuebingen - GermanyFull name of third inventor: Hubert LOEWENHEIMInventor's Signature [Signature]Date 28.05.2000Residence: D-72076 Tuebingen - GermanyCountry of Citizenship: GermanyPost Office Address: Philipp-von-Heck-Strasse 1, D-72076 Tuebingen - Germany

Full name of fourth inventor: _____

Inventor's Signature _____

Date _____

Residence: _____

Country of Citizenship: _____

Post Office Address: _____